Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: A case-control study nested in the Japan Collaborative Cohort (JACC) study

Kenji Wakai, Yoshinori Ito, Koji Suzuki, Akiko Tamakoshi, Nao Seki, Masahiko Ando, Kotaro Ozasa, Yoshiyuki Watanabe, Takaaki Kondo, Yoshikazu Nishino, Yoshiyuki Ohno, M. Mori, Y. Motohashi, I. Tsuji, Y. Nakamura, H. Iso, H. Mikami, S. Hashimoto, Y. Inaba, Y. HoshiyamaH. Suzuki, H. Shimizu, H. Toyoshima, S. Tokudome, S. Kikuchi, A. Koizumi, T. Kawamura, T. Miki, C. Dale, K. Sakata, T. Nose, N. Hayakawa, T. Yoshimura, K. Fukuda, N. Okamoto, H. Shio, T. Kitagawa, T. Kuroki, K. Tajima, T. Shimamoto, H. Tanaka, S. Hisamichi, M. Nakao, T. Suzuki, T. Hashimoto, T. Ishibashi, Kunio Aoki, Haruo Sugano, Kei Nakachi, Shuji Hashimoto

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.

Original languageEnglish
Pages (from-to)1279-1286
Number of pages8
JournalJapanese Journal of Cancer Research
Volume93
Issue number12
DOIs
Publication statusPublished - 01-12-2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: A case-control study nested in the Japan Collaborative Cohort (JACC) study'. Together they form a unique fingerprint.

  • Cite this

    Wakai, K., Ito, Y., Suzuki, K., Tamakoshi, A., Seki, N., Ando, M., Ozasa, K., Watanabe, Y., Kondo, T., Nishino, Y., Ohno, Y., Mori, M., Motohashi, Y., Tsuji, I., Nakamura, Y., Iso, H., Mikami, H., Hashimoto, S., Inaba, Y., ... Hashimoto, S. (2002). Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: A case-control study nested in the Japan Collaborative Cohort (JACC) study. Japanese Journal of Cancer Research, 93(12), 1279-1286. https://doi.org/10.1111/j.1349-7006.2002.tb01235.x